PRO-AZITHROMYCINE TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)

Sẵn có từ:

PRO DOC LIMITEE

Mã ATC:

J01FA10

INN (Tên quốc tế):

AZITHROMYCIN

Liều dùng:

250MG

Dạng dược phẩm:

TABLET

Thành phần:

AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

30/100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

OTHER MACROLIDES

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0126072001; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2008-09-25

Đặc tính sản phẩm

PRODUCT MONOGRAPH
PR
PRO-AZITHROMYCINE
Azithromycin Tablets
250 mg
USP
ANTIBACTERIAL AGENT
PRO DOC LTÉE
2925, boul. Industriel
Laval, Québec
H7L 3W9 DATE OF REVISION:
May 28, 2019
Control number: 227600
_PRO-AZITHROMYCINE Product Monograph _
_Page 2 of 71_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................3
INDICATIONS AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS
......................................................................................................6
WARNINGS AND PRECAUTIONS
....................................................................................6
ADVERSE REACTIONS
....................................................................................................11
DRUG INTERACTIONS
.....................................................................................................18
DOSAGE AND
ADMINISTRATION.................................................................................23
OVERDOSAGE
...................................................................................................................24
ACTION AND CLINICAL PHARMACOLOGY
...............................................................25
STORAGE AND STABILITY
............................................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................29
PART II: SCIENTIFIC INFORMATION
................................................................................30
PHARMACEUTICAL INFORMATION
............................................................................30
CLINICAL TRIALS
............................................................................................................31
DETAILED
PHARMACOLOGY.................................................................